MDL 3094 · Eastern District of Pennsylvania
Had gut harm after Ozempic or a related drug? Ask your doctor about care and a lawyer about a claim.
Updated 13 sources
See If You Qualify
Free · No obligation · About 2 minutes
Updated 13 sources
This may apply to you if
The process
You answer a few questions
About two minutes. Nothing is sent until you agree on the last step and press submit.
A lawyer looks at it
A lawyer at the firm reads your answers and checks them against the current case criteria.
The firm decides and gets in touch
If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.
At a glance
Who qualifies
These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.
Karen Spencer Marston · United States District Court for the Eastern District of Pennsylvania · United States District Judge
Finding: The August 28, 2026 order set a September 14–18 evidence hearing in the gut case group. A hearing date is not a verdict or a personal payment date.
GI evidence-hearing scheduling order, Document 881 (opens in a new tab) · Aug 28, 2026 · Checked Oct 3, 2026
Mohit Sodhi · Faculty of Medicine, University of British Columbia · First-listed study author
Finding: The 2023 JAMA claims-record study found links between semaglutide or liraglutide use and some gut diagnoses. The observed links do not prove the cause of one person’s illness.
Sodhi original gastrointestinal cohort study (opens in a new tab) · Oct 5, 2023 · Checked Oct 3, 2026
University of British Columbia and StatExpert Ltd · JAMA · 2023
Read the source: Claims-record study of two GLP-1 drugs and gut diagnoses (opens in a new tab) · Checked Oct 3, 2026
Not covered by this case
Check how the fee is worked out and which costs you owe, including after a loss.
Source: ABA Model Rule 1.5 fee questions · as of Oct 3, 2026
The federal access rule permits some limited copying charges and excludes some records.
Source: Federal covered-record access rule · as of Oct 3, 2026
List the drug, dates, symptoms and diagnosis. Bring records you have and note what is missing.
Source: NIDDK gastroparesis diagnosis · as of Oct 3, 2026
Ask which diagnosis, court work and time limit apply to your claim. A website inquiry is not a filed lawsuit.
Source: U.S. Courts civil-case guide · as of Oct 3, 2026
Ask who will handle the claim and what fees and costs you may owe. Check any earlier agreement with a lawyer.
Source: ABA Model Rule 1.5 fee questions · as of Oct 3, 2026
Type 2 diabetes patients: 8.9% NAION risk on semaglutide vs 1.8% on non-semaglutide medications
Gastroparesis hazard ratio: 3.67 (95% CI 1.15-11.90)
37% increased relative risk of gallbladder disease across 76 RCTs
If you used Ozempic and later had a serious stomach or bowel illness, ask a lawyer about a claim. Your doctor should guide care, and the federal case group does not decide your own result.
If you used Ozempic or a drug named in the gut cases, ask a lawyer to review your illness. The court papers describe claims about poor warnings and serious gut harm. They do not make every user eligible.
Start with the exact medicine, the dates you used it and the diagnosis in your chart. The court names Ozempic, Wegovy and Rybelsus, made by Novo Nordisk, and Trulicity and Mounjaro, made by Lilly. Tell the lawyer the brand you actually used rather than choosing one from a list.
Ask your doctor to assess your symptoms and possible causes. Gastroparesis means the stomach empties too slowly because its muscles work poorly. Feeling sick after a shot does not, by itself, show that you have this disorder or prove that a drug caused it.
Diabetes is a known cause of this condition, and in many people the cause is not found. Give your doctor and lawyer the full history, including symptoms before the drug. Do not leave out an earlier illness because you fear it will weaken your claim.
If you used the drug for weight loss, say so. Also say if you have diabetes, used a compounded product, or changed brands. Ask how those facts affect the claim. This page gives no rule about how many shots, months of use or hospital stays a firm requires.
The federal court groups gut injury claims in Pennsylvania under case group 3094. Judge Karen Spencer Marston oversees that work. The latest dated order reviewed here set a September 2026 evidence hearing; later rulings need to be checked.
The August 28, 2026 order set the hearing for September 14 through 18. It is a hearing schedule, not a trial result or payment notice. This page does not claim to know what the judge ruled after it.
Grouping cases lets a court handle shared issues before trial. A civil case still needs proof of the claimed harm and the company’s role. Ask the lawyer which court rules apply to your records and what has changed since the dated source on this page.
Vision cases are separate. A December 15, 2025 order created group 3163 for claims about NAION, a specific optic nerve injury. The panel put it before the same judge but declined to fold it into the gut case group. Shared drugs do not make these the same injury.
If you have both gut and vision problems, tell your doctors and the lawyer about both. Ask which diagnoses and case groups apply. Use the separate GLP-1 vision-loss hub for that topic; do not treat the gut page as a vision claim screen.
The scheduling and transfer orders reviewed here do not give a personal payout figure. They concern court work, not what your claim is worth. Ask a lawyer to explain what proof is needed before discussing a possible result.
A civil claim can seek money for harm, but an allegation is not an award. The court may decide responsibility and damages, or the parties may reach an agreement. Do not plan bills around a number from an ad or a result in someone else’s case.
Keep notes about care costs, missed work and changes in daily life, and keep the records that support them. Ask which losses the relevant law allows a claim to seek. This is a way to prepare questions, not a payout formula or a promise that every loss will be paid.
If a firm discusses an offer, ask to see the terms in writing. Ask what happens to fees and case costs before money reaches you. The sources reviewed here do not establish a current payment date, award grid or the terms of any private agreement.
Ask the firm for its fee and expense terms before you sign. Check what you may owe if the case ends with no money. The court records do not tell us this site’s partner prices or the cost of a first inquiry.
The ABA model fee rule describes a signed written agreement for a fee based on the result. It calls for the fee calculation and expense terms to be explained. It also addresses costs a client could owe without winning. It is a model rule, not proof of your state’s rule.
Ask who pays to obtain records, for expert work and for other case expenses. Ask whether costs come out before or after the firm calculates its share. Request a plain example using the actual written terms. This page does not supply a percentage or promise no charges.
For medical records, the federal access rule allows some limited copying charges. Ask the provider about the format and price before ordering copies. Do not assume a health-record request is always free, or that every record you want is covered by that rule.
If you already have a lawyer for this injury, ask that lawyer before signing another agreement. Describe any forms you have sent or signed. Ask each firm to explain its role and how existing representation affects the next step; do not guess from the number of ads you see.
Ask a lawyer to check the time limit for your own claim. Filing periods depend on the claim and the law that applies. The date of a court hearing is not your personal filing deadline.
Bring the dates you first used the drug, first had symptoms, received a diagnosis and learned about a possible link. Tell the lawyer where you lived at those times. Ask which facts matter under the relevant law rather than treating this page as a date calculator.
A request for legal help is not the same as filing a lawsuit. Ask the lawyer what has actually been filed, which court is involved and whether any deadline is approaching. Get an explanation of the action needed rather than relying on the date of an online inquiry.
An old prescription or an earlier diagnosis needs its own review. This page does not decide that a past user has time left or has missed the filing period. Ask how the law treats your actual history, including any prior lawsuit or written agreement.
Contact your health team about severe or lasting stomach symptoms. Ask your prescriber how to manage your medicine and care. Keep that medical decision separate from a claim check; this page does not tell you to stop or change therapy.
NIDDK advises prompt medical help for severe stomach pain, blood in vomit, prolonged vomiting or trouble breathing. Seek care for those symptoms rather than waiting for a lawyer’s reply. Your doctor must assess the cause and the treatment you need.
Start a simple list of medicines and dates. Note dose changes, symptoms, visits and the diagnosis you were given. Mark a date as an estimate if you are not sure. Keep your own account separate from what a test report says, so a reviewer can see which is which.
Ask your clinic how to request prescription, visit and test records it holds. Ask for the written report of any stomach-emptying test you already had. Do not seek a test just to match an online claim checklist; discuss testing and its purpose with your treating doctor.
Keep a copy of your request and ask how the provider will send the records. The federal rule generally allows 30 days to act, with one properly noticed extension. Some records are excluded. Ask about the status of your request rather than assuming an instant or complete transfer.
Prepare your drug and health history, ask the firm what it needs, then review any terms before signing. Those are preparation steps, not a verified promise about this site’s intake. A website inquiry alone is not a filed lawsuit.
First, write down the exact drug, the illness in your chart and key dates. Bring the records you already have and list what is missing. Ask who would request the rest. A list of missing records is more useful than making up a diagnosis or a date.
Next, ask who is assessing the claim and which injury it concerns. For a gut diagnosis, ask about the gut case group. For a diagnosed vision injury, ask about the separate group. Ask what current court decisions mean for a person with your records.
Before you share medical details, ask who receives them, how they are used and how to contact the firm. Read the consent and fee terms. This package has not verified a partner’s privacy policy, response time or charges; the court records cannot supply those service facts.
If a firm can offer representation, ask it to explain the written agreement and the next step. If it cannot, ask whether it is declining under its own screen or because of a legal rule. Do not use either reply as a diagnosis or a reason to delay needed care.
A 2023 study found links between some GLP-1 drugs and certain gut diagnoses in claims records. It was not proof that a drug caused one person’s illness. The Ozempic label also describes severe gut reactions and advice to contact a provider.
The JAMA study compared records for 5,411 users of three medicines. The two GLP-1 drugs studied were semaglutide and liraglutide. The comparison drug was bupropion-naltrexone. Participants had obesity codes without diabetes codes; the researchers could not confirm every person’s reason for use.
The pooled GLP-1 group had higher rates of pancreatitis, bowel blockage and delayed stomach emptying than the comparison group. It was an observed link, not a randomized test. The study lacked body-mass-index data and relied on claims codes. Its results do not establish risk for every drug in this class.
The FDA-hosted Ozempic label reviewed here was revised in May 2026. It says severe gut reactions can occur and that Ozempic is not recommended with severe gastroparesis. Discuss that wording and your symptoms with your prescriber. A label warning does not decide a legal claim.
NIDDK explains that doctors use history, examination and tests to assess delayed stomach emptying and rule out other problems. A useful claim review starts with that actual medical record. Do not turn an ad, a study or this page into your own diagnosis.
The answers below focus on this drug and these gut claims. They explain questions to raise, not a guarantee that a firm will accept your case. Vision claims, medical care and individual time limits need their own review.
The linked sources separate court allegations, clinical guidance and research findings. Check their dates and scope when asking about your own care or claim. A source citation does not mean its author reviewed or endorsed this page.
GLP-1 receptor agonists produce their weight-loss and blood-sugar effects by dramatically slowing gastric emptying. In a significant subset of patients, this slowing becomes pathological, leading to gastroparesis, bowel obstruction, and other severe conditions.
GLP-1 drugs activate receptors in the stomach that suppress gastric motility. In susceptible patients, the suppression becomes severe enough to cause gastroparesis — a condition where the stomach cannot empty food normally. Symptoms include severe nausea, vomiting, abdominal pain, bloating, and malnutrition. The condition may persist even after discontinuing the drug.
The motility-suppressing effects of GLP-1 agonists extend beyond the stomach to the small and large intestine. Severe slowing can cause ileus (intestinal shutdown) or mechanical bowel obstruction, which can be life-threatening and may require emergency surgery.
GLP-1 receptors are present on pancreatic acinar cells. Overstimulation may trigger acute pancreatitis — inflammation of the pancreas that causes severe abdominal pain, nausea, and in severe cases organ failure. The JAMA 2023 study found a 9.09x increased risk.
GLP-1 drugs may cause sudden, painless vision loss by reducing blood flow to the optic nerve. Studies show semaglutide users face 4-8x higher NAION risk. The mechanism may involve rapid weight loss affecting vascular perfusion or direct vascular effects of GLP-1 receptor activation.
The harm mechanism evidence supports failure-to-warn claims: the GI risks were known or knowable from clinical trial data and post-market surveillance, yet the manufacturers failed to update labels to warn about gastroparesis specifically until January 2025 — years after millions of prescriptions.
Gastroparesis is a condition in which the stomach cannot empty food at a normal rate due to impaired motility. When caused by GLP-1 receptor agonists, the drug's activation of GLP-1 receptors in the stomach suppresses gastric motility to a pathological degree. Unlike diabetic gastroparesis (which develops gradually over years), drug-induced gastroparesis can develop rapidly — within weeks to months of starting the medication.
Prognosis varies significantly. Some patients improve after discontinuing the GLP-1 drug, but recovery may take months. A subset of patients develop persistent gastroparesis that does not resolve after drug discontinuation, requiring long-term management. Severe cases may require surgical intervention or permanent dietary modifications.
The risk and type of injury from GLP-1 drugs varies based on the specific drug, dosage, duration of use, and whether the drug was prescribed for diabetes or weight loss.
Semaglutide or Tirzepatide for Weight Loss
Semaglutide or Tirzepatide for Type 2 Diabetes
Semaglutide Use with Vision Loss
Each case is evaluated individually. The strength of a claim depends on your specific drug, dosage, timeline, diagnosis, and medical history. Consult an attorney for a case-specific evaluation.
The GLP-1 litigation targets two of the world's most profitable pharmaceutical companies, even as they continue to generate record revenue from the drugs at issue.
The GLP-1 litigation coincides with growing public concern about pharmaceutical pricing, marketing practices, and the safety of rapid weight-loss drugs.
No settlement has been announced, and no one can say what the litigation will cost either company.
Regulatory agencies have taken incremental action on GLP-1 drug safety, but plaintiffs argue that both the FDA and the manufacturers have been too slow to act given the severity of the adverse events.
The pattern of delayed regulatory action supports plaintiffs' failure-to-warn claims: the risks were known or knowable from clinical trial data and post-market surveillance, yet label updates came years after millions had been prescribed the drugs.
The statute of limitations for GLP-1 drug injury claims is typically triggered by the diagnosis of the injury — not by when you started taking the drug. The discovery rule applies in most states.
For pharmaceutical injury claims, most states start the SOL clock when the patient is diagnosed with the condition (gastroparesis, NAION, etc.) or when they knew or should have known that the drug caused their condition. Given that gastroparesis and NAION were not widely known side effects of GLP-1 drugs until the 2023-2024 scientific publications, the discovery rule may extend filing deadlines for patients who were injured before these risks became public knowledge.
California's 2-year SOL from discovery applies. She likely became aware of the connection to her GLP-1 medication after the October 2023 JAMA study. Her SOL likely runs from late 2023 or early 2024 when the connection became publicly known.
Pennsylvania's 2-year SOL from injury/discovery applies. As the MDL home state, Pennsylvania courts are familiar with GLP-1 claims. A lawyer can tell him how that deadline applies to his facts.
Florida has a 4-year products liability SOL. She has until approximately 2026-2027 to file, depending on when she discovered the drug connection. Florida's longer SOL is favorable.
If you were diagnosed with gastroparesis, bowel obstruction, pancreatitis, gallbladder disease, or NAION while taking or after taking an Ozempic-class drug, a lawyer can check how your state's deadline applies to you. Whether that time has passed depends on your facts, so don't rule yourself out. A lawyer can tell you.
Your state
Deadlines vary by state and by case. A lawyer can confirm yours.
It depends on the facts of the Ozempic or GLP-1 issue. The source reviewed here gives public context, but it does not decide causation, eligibility, payment, or deadline for one person. A lawyer can review your records and the law that applies.
Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026
It depends on the facts of the Ozempic or GLP-1 issue. The source reviewed here gives public context, but it does not decide causation, eligibility, payment, or deadline for one person. A lawyer can review your records and the law that applies.
Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026
It depends on the facts of the Ozempic or GLP-1 issue. The source reviewed here gives public context, but it does not decide causation, eligibility, payment, or deadline for one person. A lawyer can review your records and the law that applies.
Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026
It depends on the facts of the Ozempic or GLP-1 issue. The source reviewed here gives public context, but it does not decide causation, eligibility, payment, or deadline for one person. A lawyer can review your records and the law that applies.
Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026
No. Doctors use your history, exam and tests to assess slow stomach emptying and rule out other problems. A symptom or an online description cannot establish your diagnosis, cause or outlook.
Source: NIDDK: Diagnosis of Gastroparesis · as of Oct 7, 2026
It depends. The public Ozempic or GLP-1 court source reviewed here addresses procedure or case status. It does not decide an individual person's claim, payment, or deadline. A lawyer can check the current docket and your records.
Source: E.D. Pa. MDL 3094 GLP-1 RA Products Liability Litigation overview · as of Oct 7, 2026
It depends. Ask your prescriber or specialist about diagnosis, testing, and medication changes. The Ozempic label lists serious gastrointestinal warnings and postmarketing reports, but it does not decide what caused one person's injury. Keep prescription, hospital, test, and diagnosis records for review.
Source: FDA Ozempic prescribing information, revised May 2026 · as of Oct 7, 2026
The December 2025 order placed NAION claims in separate group 3163, rather than gut group 3094. The groups share a judge but concern different alleged injuries. Ask which applies to your diagnosis.
Source: JPML MDL 3163 Transfer Order · as of Oct 7, 2026
Checked against 13 primary sources by People's Justice editors · Updated
How we make moneyThe review is free and private. Asking for it doesn’t commit you to anything.
Register your interest